Provider Training

ACCREDITATION INFORMATION

CEI is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE). The following course is approved for 16.0 contact hour of CPE credit (1.6 CEUs). The ACPE Universal Activity Number for this activity is: 0107-9999-19-337-H01-P (pharmacists).

Available: October 26, 2019
Expiration Date: October 25, 2022

To obtain 16.0 contact hours of CPE credit for completing this course, “Pharmacogenomics,” participants must pre-register online, participate in the entire course, pass the final exam with a score of at least 70%, and complete the CPE assessment and evaluation questions.

ON DEMAND: To obtain 16.0 contact hours of continuing pharmacy education credit (1.6 CEUs), participants must pre-register for the course on the RxGenomix website (rxgenomix.com), complete the entire on-demand course, and pass the mid and final exams with scores of at least 70%.  Once completed, you will receive a code from RxGenomix and instructions on how to access the evaluation on the CEImpact LMS . Once the evaluation is successfully completed, click the Submit button. The CPE Statement of Credit can then be accessed on CPE Monitor, www.MyCPEMonitor.net.

TARGET AUDIENCE

• Pharmacists

ACPE ACTIVITY TYPE

Knowledge-based

ACTIVITY FEE

There is a fee of $349 associated with this activity.

DEVELOPMENT

“Pharmacogenomics” is a home study continuing education activity for pharmacists developed by RxGenomix.

SYSTEM REQUIREMENTS

The RxGenomix learning portal is designed to work with any current web browser. If you have any technical difficulties, please contact RxGenomix: info@rxgenomix.com. For best results, the following system capabilities are recommended:

WINDOWS

• Windows XP, Windows 2003 or Windows Vista
• Display resolution of 800×600 or higher
• Microsoft Internet Explorer 6.0 SP1 or later, Firefox 2.0 or later, or Google Chrome 1.0
• For Firefox and Chrome, Silverlight 1.0 or later
• Windows Media Player 9.0 or later
• Broadband Internet connection (256 Kbps or more)
• No network blocks or filters that disable streaming media

MAC

• Mac OS X 10.5 or later
• Safari 2.0.4 or later (or Firefox 2.0 or later) Silverlight 1.0
• Broadband Internet connection (256 Kbps or more)
• No network blocks or filters that disable streaming media.

FACULTY

David Bright, PharmD, BCACP
Associate Professor of Pharmacy
Ferris State University

David Kisor, BS, PharmD, FCP
Professor of Pharmaceutical Sciences and Pharmacogenomics
Manchester University

Director of Pharmacogenomics Programs
Manchester University

Brad Tice, PharmD, MBA, FAPhA
Founder and Shareholder, RxGenomix

DISCLOSURES

David Bright, PharmD, BCACP declares financial interests for the following:

David Kisor, BS, PharmD, FCP declares financial interests for the following:

Brad Tice, PharmD, MBA, FAPhA declares financial interests for the following:

At the completion of this activity, pharmacists and pharmacy technicians will be able to:

1. Define pharmacogenetics (PGt), pharmacogenomics (PGx), and the related nomenclature.
2. Explain the scientific basis of genetic influence on pharmacokinetics (PK) and pharmacodynamics (PD) related to drug and/or drug dose selection.
3. Describe the types of DNA samples for PGt/PGx testing.
4. Interpret PGt/PGx test results.
5. Identify drug-gene and drug-drug-gene interactions in medication lists.
6. Associate genetic and non-genetic factors which define a patient’s phenotype relative to response to medication therapy.
7. Recommend specific alternative therapies and/or doses of specific medications based on PGt/PGx results.
8. Relate pharmacist competencies in PGt/PGx to science and application.